Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of Ex-Vivo Expanded Allogeneic Universal Donor (UD) TGFbi NK Cell Infusions in Combination With Temozolomide as a Lymphodepleting Agent in Patients With Melanoma Metastatic to the Brain
Conditions
Interventions
Natural Killer Cell Therapy
Temozolomide
Locations
1
United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Start Date
March 1, 2023
Primary Completion Date
April 15, 2026
Completion Date
April 15, 2026
Last Updated
January 12, 2026
NCT04693377
NCT06500455
NCT05039801
NCT06066138
NCT06391099
NCT04988009
The Ohio State University Comprehensive Cancer Center
CONTACT
800-293-5066OSUCCCClinicaltrials@osumc.eduLead Sponsor
Kari Kendra
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions